Corticosteroids for Asthma
(AirPATH Trial)
Trial Summary
What is the purpose of this trial?
Most individuals with asthma can effectively manage their symptoms and maintain normal lung function using inhaled medications, unfortunately, there is a subset of asthma sufferers whose symptoms, lung function, and risk of asthma attacks remain unimproved despite conventional inhaled medications. There could be several reasons for this. One possibility is that inhaled medications fail to reach the intended areas within the lungs, due to structural abnormalities within the airways themselves. Much like road conditions or closures can impede the speed and efficiency of vehicle travel, factors such as airway narrowing or mucus blockages, which are common in asthma, can obstruct the passage of inhaled medications through the airways. Our team has now optimized advanced medical imaging techniques, including magnetic resonance imaging (MRI) and computed tomography (CT), required to investigate this. This study will use these imaging methods to visually assess and measure individual patients' airways and determine whether abnormal airway structures impact how well they respond to inhaled and orally delivered medications. We anticipate finding that abnormal airway structures make inhaled medications less effective, but that they do not affect the response to oral medications.
Eligibility Criteria
This trial is for asthma patients who don't get better with regular inhaled meds. It's likely because the meds can't reach all parts of their lungs due to airway issues like narrowing or mucus. To join, they need a detailed lung scan using MRI or CT.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Inhaled corticosteroid (ICS)
- Oral Corticosteroid (OCS)
Find a Clinic Near You
Who Is Running the Clinical Trial?
McMaster University
Lead Sponsor